Inhibrx Biosciences (INBX) Research & Development (2023 - 2026)
Inhibrx Biosciences (INBX) recorded Research & Development of $23.9 million in Q2 2026, up 7.3% from $22.27 million a year earlier.
Powered by 
Analysis
Inhibrx Biosciences (INBX) Research & Development (2023 - 2026) Analysis & Trends
On a TTM basis, Inhibrx Biosciences' Research & Development came in at $100.05 million as of Jun 30, 2026, down 23.9% year-over-year; for FY2025, it was $113.03 million, down 44.5% from FY2024.
- Across earlier years, Research & Development came in at $203.74 million in FY2024 (+6.3%) and $191.64 million in FY2023.
- Quarterly Research & Development has ranged from $22.27 million in Q2 2025 to $82.09 million in Q4 2023 over the past five years.
- On a year-over-year basis, Research & Development rose in two of the last seven quarters, with an average decline of 30.0%.
- Peak year-over-year performance for Research & Development in the last five years was growth of 98.3% in Q2 2024, against a decline of 67.1% in Q2 2025 at the low end.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 3.65 Bn |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | 2.34 Bn |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 9.74 Bn |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | -2.85 Bn |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | -4.05 Bn |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 1.87 Bn |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | 1.76 Bn |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 2.81 Bn |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 993.80 Mn |
| 10 | Inhibrx Biosciences | 1.50 Bn | 1.50 Bn | - | 23.90 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 23.90 Mn |
| Dec 31, 2025 | 25.35 Mn |
| Sep 30, 2025 | 28.54 Mn |
| Jun 30, 2025 | 22.27 Mn |
| Mar 31, 2025 | 36.88 Mn |
| Dec 31, 2024 | 33.37 Mn |
| Sep 30, 2024 | 38.89 Mn |
| Jun 30, 2024 | 67.63 Mn |
| Mar 31, 2024 | 63.85 Mn |
| Dec 31, 2023 | 82.09 Mn |
| Sep 30, 2023 | 38.06 Mn |
| Jun 30, 2023 | 34.11 Mn |
API Access
Inhibrx Biosciences Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=INBX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "INBX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=INBX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();